Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study Felip, E., Altorki, N. K., Zhou, C., Vallieres, E., Vynnychenko, I. O., Akopov, A., Martinez-Marti, A., Chella, A., Bondarenko, I., Ursol, G., Levchenko, E., Kislov, N., Liersch, R., Belleli, R., McNally, V. A., Bennett, E., Gitlitz, B. J., Wakelee, H. ELSEVIER. 2022: S71

View details for DOI 10.1016/j.annonc.2022.02.090

View details for Web of Science ID 000778453100082